PRL modulates cell cycle regulators in mammary tumor epithelial cells

被引:85
作者
Schroeder, MD [1 ]
Symowicz, J [1 ]
Schuler, LA [1 ]
机构
[1] Univ Wisconsin, Dept Comparat Biosci, Madison, WI 53706 USA
关键词
D O I
10.1210/me.16.1.45
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PRL is essential for normal lobulo-alveolar growth of the mammary gland and may contribute to mammary cancer development or progression. However, analysis of the mechanism of action of PRL in these processes is complicated by the production of PRL within mammary epithelia. To examine PRL actions in a mammary cell-specific context, we selected MCF-7 cells that lacked endogenous PRL synthesis, using PRL stimulation of interferon-gamma -activated sequence-related PRL response elements. Derived clones exhibited a greater proliferative response to PRIL than control cells. To understand the mechanism, we examined, by Western analysis, levels of proteins essential for cell cycle progression as well as phosphorylation of retinoblastoma protein. The expression of cyclin D-1, a critical regulator of the G(1)/S transition, was significantly increased by PRL and was associated with hyperphosphorylation of retinoblastoma protein at Ser(780). Cyclin BI was also increased by PRL. In contrast, PRL decreased the Cip/Kip family inhibitor, p21, but not p16 or p27. These studies demonstrate that PRL can stimulate the cell cycle in mammary epithelia and identify specific targets in this process. This model system will enable further molecular dissection of the pathways involved in PRL-induced proliferation, increasing our understanding of this hormone and its interactions with other factors in normal and pathogenic processes.
引用
收藏
页码:45 / 57
页数:13
相关论文
共 66 条
[1]  
BABLINGRAY J, 1996, P NATL ACAD SCI USA, V93, P15215
[2]  
Barnes DM, 1997, J PATHOL, V181, P267, DOI 10.1002/(SICI)1096-9896(199703)181:3<267::AID-PATH783>3.0.CO
[3]  
2-X
[4]   Extrapituitary prolactin: Distribution, regulation, functions, and clinical aspects [J].
BenJonathan, N ;
Mershon, JL ;
Allen, DL ;
Steinmetz, RW .
ENDOCRINE REVIEWS, 1996, 17 (06) :639-669
[5]   Prolactin (PRL) and its receptor: Actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice [J].
Bole-Feysot, C ;
Goffin, V ;
Edery, M ;
Binart, N ;
Kelly, PA .
ENDOCRINE REVIEWS, 1998, 19 (03) :225-268
[6]  
BOOT LM, 1962, GEN COMP ENDOCR, V2, P601
[7]   TARGETING OF AN INDUCIBLE TOXIC PHENOTYPE IN ANIMAL-CELLS [J].
BORRELLI, E ;
HEYMAN, R ;
HSI, M ;
EVANS, RM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (20) :7572-7576
[8]   Prolactin controls mammary gland development via direct and indirect mechanisms [J].
Brisken, C ;
Kaur, S ;
Chavarria, TE ;
Binart, N ;
Sutherland, RL ;
Weinberg, RA ;
Kelly, PA ;
Ormandy, CJ .
DEVELOPMENTAL BIOLOGY, 1999, 210 (01) :96-106
[9]   A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence [J].
Carroll, JS ;
Prall, OWJ ;
Musgrove, EA ;
Sutherland, RL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (49) :38221-38229
[10]  
Chen WY, 1999, CLIN CANCER RES, V5, P3583